We are live on ! Find out more
NVS icon

Novartis

919 hedge funds and large institutions have $22.3B invested in Novartis in 2014 Q4 according to their latest regulatory filings, with 101 funds opening new positions, 335 increasing their positions, 320 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

137% more call options, than puts

Call options by funds: $183M | Put options by funds: $76.9M

115% more first-time investments, than exits

New positions opened: 101 | Existing positions closed: 47

5% more funds holding

Funds holding: 875919 (+44)

5% more repeat investments, than reductions

Existing positions increased: 335 | Existing positions reduced: 320

0.05% more ownership

Funds ownership: 9.72%9.77% (+0.05%)

1% less capital invested

Capital invested by funds: $22.5B → $22.3B (-$272M)

13% less funds holding in top 10

Funds holding in top 10: 7162 (-9)

Holders
919
Holders Change
+44
Holders Change %
+5.03%
% of All Funds
24.5%
Holding in Top 10
62
Holding in Top 10 Change
-9
Holding in Top 10 Change %
-12.68%
% of All Funds
1.65%
New
101
Increased
335
Reduced
320
Closed
47
Calls
$183M
Puts
$76.9M
Net Calls
+$106M
Net Calls Change
+$28.1M
Name Holding Trade Value Shares
Change
Change in
Stake
Dodge & Cox
1
Dodge & Cox
California
$4.66B -$53.7M -648,177 -1%
Primecap Management
2
Primecap Management
California
$2.05B -$6.55M -78,979 -0.3%
BBHC
3
Brown Brothers Harriman & Co
New York
$962M -$87.9M -1,060,149 -8%
Wells Fargo
4
Wells Fargo
California
$703M +$17.9M +216,177 +3%
BTS
5
BB&T Securities
Virginia
$596M -$2.29M -27,588 -4%
Fisher Asset Management
6
Fisher Asset Management
Washington
$557M -$728K -8,781 -0.1%
UBS Group
7
UBS Group
Switzerland
$452M +$451M +5,438,424 New
MAA
8
Managed Account Advisors
New Jersey
$368M -$6.23M -75,146 -2%
Northern Trust
9
Northern Trust
Illinois
$354M +$45.8M +552,845 +15%
Loomis, Sayles & Company
10
Loomis, Sayles & Company
Massachusetts
$324M +$6.34M +76,469 +2%
Invesco
11
Invesco
Georgia
$283M +$9.96M +120,115 +4%
Franklin Resources
12
Franklin Resources
California
$268M +$24.8M +298,921 +10%
Parnassus Investments
13
Parnassus Investments
California
$254M -$5.39K -65 -0%
Fidelity Investments
14
Fidelity Investments
Massachusetts
$249M +$15.3M +184,940 +7%
ClearBridge Investments
15
ClearBridge Investments
New York
$234M -$17.9M -215,614 -7%
Capital Research Global Investors
16
Capital Research Global Investors
California
$233M
Boston Partners
17
Boston Partners
Massachusetts
$213M -$5.66M -68,319 -3%
Bank of America
18
Bank of America
North Carolina
$212M -$6.1M -73,601 -3%
EARNEST Partners
19
EARNEST Partners
Georgia
$209M +$4.36M +52,570 +2%
WI
20
WHV Investments
California
$207M -$9.53M -115,001 -4%
Neuberger Berman Group
21
Neuberger Berman Group
New York
$198M -$22.1M -266,798 -10%
Morgan Stanley
22
Morgan Stanley
New York
$192M +$20.5M +247,162 +12%
Lazard Asset Management
23
Lazard Asset Management
New York
$190M -$103K -1,239 -0.1%
Dimensional Fund Advisors
24
Dimensional Fund Advisors
Texas
$190M -$125K -1,503 -0.1%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$181M +$63.7M +768,719 +55%

NVS Hedge Fund Activity: Q4 2014 in Review

919 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q4 2014, worth a combined $22.3B — down 1.2% from $22.5B a quarter earlier.

Buyers outnumbered sellers: 101 funds opened new NVS positions and 47 closed out — a net gain of 54 holders — while 335 added to existing stakes and 320 trimmed.

The largest buyer was Sterling Capital Management, adding an estimated $71.7M. The largest seller was Arrowstreet Capital, cutting an estimated $106M.

  • 919 institutional investors held Novartis (NVS) as of Q4 2014, up from 875 in Q3 2014.
  • Funds reported $22.3B of Novartis stock for Q4 2014, down 1.2% quarter-over-quarter.
  • 101 funds opened new Novartis positions in Q4 2014 and 47 closed out, a net change of +54 holders.
  • The largest Novartis buyer in Q4 2014 was Sterling Capital Management, an estimated $71.7M added.
  • The largest Novartis seller in Q4 2014 was Arrowstreet Capital, an estimated $106M sold.

Based on aggregated 13F filings for Q4 2014.